Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,

Slides:

Advertisements

Similar presentations

SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.

Advertisements

ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,

OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:

For OMA distribution only. Trademarks may be registered and are the property of their respective owners. © 2014 Medtronic, Inc. All rights reserved DOC_1A.

FAME 2 year Objective:To investigate the 2-year outcome of PCI guided by FFR in patients with multivessel CAD. Study:Multicenter, single blind, randomized.

A Randomized Comparison of a Sirolimus-eluting Stent with Biodegradable Polymer versus an Everolimus-eluting Stent with a Durable Polymer for Percutaneous.

Five-Year Follow-up of Safety and Efficacy of the Resolute Zotarolimus-Eluting Stent: Insights from the RESOLUTE Global Clinical Trial Program in Approximately.

3rd CEEGI Advisory Board1 Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac.

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs. Everolimus-Eluting Stents for Treatment of Unprotected Left Main Coronary Artery Lesions Julinda Mehilli,

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

ISAR-TEST 5: Randomized, Non-inferiority Trial of Rapamycin/Probucol- and Zotarolimus-Eluting Stents J. Mehilli, MD A. Kastrati, R.A. Byrne, S. Massberg,

Clinical Result Overview

DR ALEX CHASE REGIONAL HEART CENTRE MORRISTON SWANSEA SLIDE MATERIAL:PERSONAL COMMUNICATION WITH AUTHORS ABBOTT, BOSTON SCIENTIFIC, CORDIS, MEDTRONIC TCT.

The Stent of Choice in ACS patients The Stent of Choice in ACS 1) The Rationale…

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Stents versus Bypass Surgery for Left Main disease Objective:to assess the non-inferiority of stents compared to bypass surgery for unprotected left main.

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

NOBORI New Generation Drug Eluting Stent Clinical Data Danny Detiege Clinical Manager - Cardiology Terumo Europe N.V. Leuven, Belgium.

1 of Presented by Gregg W. Stone, MD, ACC PROMUS Stent is a private-labeled Xience V Everolimus Eluting Coronary Stent System manufactured.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

A Randomized Comparison of Everolimus- Eluting Absorb Bioresorbable Vascular Scaffolds vs. Everolimus-Eluting Metallic Stents: One-Year Angiographic and.

Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.

Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

The Endeavor Zotarolimus-Eluting Stent: Device Description and Comprehensive Update of the Clinical Trial Program.

Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.

ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.

Compare Trial 2 year follow-up Peter Smits Maasstad Ziekenhuis Rotterdam The Netherlands.

For OMA distribution only. © 2014 Medtronic, Inc. All rights reserved DOC_1A 03/14 Four-Year Outcomes Following Resolute Zotarolimus-Eluting Stent.

NEXT A Prospective, Randomized Trial Comparing Cre8, a Polymer-Free Stent Eluting Sirolimus, to a Paclitaxel-Eluting Stent Didier Carrié, MD,PhD On behalf.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE

David E. Kandzari, MD on behalf of the BIONICS investigators

Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,

XIENCE V vs TAXUS: Game Over! The Studies are Definitive

SORT-OUT VI A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Bioabsorbable-Polymer Biolimus-Eluting Stent in Patients.

New Generation Resolute Integrity Drug-Eluting Stent Superior to Benchmark Xience Drug-Eluting Stent: Primary Endpoint Results from the PROPEL Study –

Two-year clinical outcomes in the EVOLVE FHU trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent Ian Meredith.

A Novel Abluminal Coated Sirolimus-Eluting Stent as a Treatment Option for Diabetic Patients: Results from an All-Comers Multi-center Study: the En-ABL.

12 Month Outcomes in Patients with Diabetes Mellitus Implanted with a Resolute Zotarolimus-eluting Stent: Initial Results from the RESOLUTE Global Clinical.

NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.

LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.

TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.

The RESOLUTE Program: today and tomorrow

On behalf of J. Belardi, M. Leon, L. Mauri,

on behalf of the ABSORB II Investigators

TAXUS II and IV: two-year follow-up

A Randomized, Prospective, Intercontinental Evaluation of a Bioresorbable Polymer Sirolimus-eluting Stent: the CENTURY II Trial: an Update with 2 Years.

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.

3-Year Clinical Outcomes From the RESOLUTE US Study

ENDEAVOR IV: 5 Year Final Outcomes

Presented at ACC 2003 Late Breaking Clinical Trials

The American College of Cardiology Presented by Dr. Raimund Erbel

SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.

On behalf of all principal COMPARE II investigators:

(p = 0.32 for noninferiority)

ENDEAVOR II Five-Year Clinical Follow-up

(p < for noninferiority)

FOR DISTRIBUTION BY MEDTRONIC OFFICE OF MEDICAL AFFAIRS ONLY.

Long-term safety and efficacy of zotarolimus-eluting and sirolimus-eluting stents in routine clinical care patients 36-month follow-up in the SORT OUT.

Gregg W. Stone, MD Columbia University Medical Center

ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.

Primary safety endpoint

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Presentation transcript:

Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter, single blind, randomized noninferiority trial. Population:Patients with stable CAD and ACS (NSTEMI, STEMI, UA). Size mm. No restrictions on no of stents, no of treated lesions, lesion length, treated vessel Endpoint: TLF: cardiac death, MI, clinically driven TLR at 1 year f-up. Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter, single blind, randomized noninferiority trial. Population:Patients with stable CAD and ACS (NSTEMI, STEMI, UA). Size mm. No restrictions on no of stents, no of treated lesions, lesion length, treated vessel Endpoint: TLF: cardiac death, MI, clinically driven TLR at 1 year f-up.

Patients enrolled N=2292 Zotarolimus DES (Endeavor- Resolute) N=1140 Everolimus DES (Xience V) N=1152 Planned f-up angio 13 m. 20% of patients Planned f-up angio 13 m. 20% of patients Resolute all comers trial

p=0.92p=0.50p=0.08p=0.94p=0.01 Event rate at 1 year f-up (%) Resolute all comers trial

Late loss (mm)QCA at 13 months f-up angio Resolute all comers trial

Serruys et al. N Engl J Med 2010;363: Conclusion:At follow-up the new generation ZES (Endeavor-Resolute) was found to be non- inferior to the everolimus eluting Xience V stent in a population of patients with minimal exclusion criteria. Resolute all comers trial